Treefrog Therapeutics key facts
- Developer of a proprietary technology platform designed to provide alternative access to cell therapies.
- It has raised $116.1M; the latest was Debt - General ($32.0M) in Nov 2024.
- Notable investors include Bpifrance, La French Tech, XAnge, BNP Paribas Développement, IRDI Capital Investissement — 21 tracked in total.
- Status: Privately Held (backing).
Who backs Treefrog Therapeutics
21+- ·The complete investor list: 21 names
- ·Watch Treefrog Therapeutics: the Monday email on marks, rounds and moves
Treefrog Therapeutics funding rounds
No funding rounds for Treefrog Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Treefrog Therapeutics investors
21 investors are on record for Treefrog Therapeutics, including Bpifrance, La French Tech, XAnge and BNP Paribas Développement. By type, the record holds 4 private equity firms and 1 venture capital firm.
About Treefrog Therapeutics
Developer of a proprietary technology platform designed to provide alternative access to cell therapies. The company's tool provides an end-to-end three-dimensional scalable service that will reduce treatment costs as well as help cell therapy players secure cell production and quality, fasten clinical development, and facilitate market access, enabling patients to access safe and affordable stem cell therapy.
- Sector
- Healthcare
- HQ
- Pessac, France
- Founded
- 2018
- Employees
- 177
- Website
- treefrog.fr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Treefrog Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.